Cynomolgus Recombinant C5 protein (V2LY-0526-LY1474)

Name: Cynomolgus Recombinant C5 protein
SKU: V2LY-0526-LY1474
Rating: 5 (1 reviews)

See all C5 antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Expressed Host

HEK293 Cells

Protein Species

Cynomolgus

Protein Construction

This product is Cynomolgus Recombinant C5 protein consist of Amino Acid: 678-751 and predicts a molecular mass of 8.41 kDa.

Molecule Mass

8.41 kDa

Verified

HPLC

Sequence

Amino Acid: 678-751

Species

Cynomolgus

Formulations & Storage [For reference only, actual COA shall prevail!]

Purity

>95% as determined by SDS-PAGE.>95% as determined by SEC-HPLC.

Endotoxin

Please contact us for more information.

Format

Lyophilized

Reconstitution

Allow the vial and reconstitution buffer to equilibrate to room temperature. Briefly centrifuge or tap down the vial to ensure that all lyophilized powder is collected at the bottom of the vial. For the reconstitution of this product, we recommend adding PBS or sterile water to achieve a final antibody concentration of 1 mg/mL. Allow the vial to reconstitute for 10-15 minutes at room temperature with gentle agitation. Avoid vigorous shaking that can cause foaming and antibody denaturation. Aliquot into volumes based on your experiment and store liquid protein at -20°C or -80°C for long time.

Buffer

Lyophilized from sterile Tris, NaCl, Glutathione, EDTA, DTT, PMSF, Glycerol

Preservative

None

Storage

Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

More Infomation

Target

Full Name

complement C5

Function

Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.
Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes (PubMed:8182049).
C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

Biological Process

Activation of MAPK activity Source: ProtInc
Cell surface receptor signaling pathway Source: ProtInc
Chemotaxis Source: ProtInc
Complement activation Source: Reactome
Complement activation, alternative pathway Source: UniProtKB-KW
Complement activation, classical pathway Source: UniProtKB-KW
Cytolysis Source: UniProtKB-KW
G protein-coupled receptor signaling pathway Source: Reactome
Inflammatory response Source: ProtInc
In utero embryonic development Source: Ensembl
Negative regulation of macrophage chemotaxis Source: BHF-UCL
Positive regulation of angiogenesis Source: Ensembl
Positive regulation of chemokine production Source: BHF-UCL
Positive regulation of vascular endothelial growth factor production Source: BHF-UCL
Regulation of complement activation Source: Reactome

Cellular Location

Secreted

Involvement in disease

Complement component 5 deficiency (C5D): A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis.
An association study of C5 haplotypes and genotypes in individuals with chronic hepatitis C virus infection shows that individuals homozygous for the C5_1 haplotype have a significantly higher stage of liver fibrosis than individuals carrying at least 1 other allele.

Ariceta, G., Dixon, B. P., Kim, S. H., Kapur, G., Mauch, T., Ortiz, S., ... & Han, K. H. (2021). The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney International, 100(1), 225-237.

Laurence, J., Mulvey, J. J., Seshadri, M., Racanelli, A., Harp, J., Schenck, E. J., ... & Magro, C. M. (2020). Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clinical Immunology, 219, 108555.

de Latour, R. P., Bergeron, A., Lengline, E., Dupont, T., Marchal, A., Galicier, L., ... & Fremeaux-Bacchi, V. (2020). Complement C5 inhibition in patients with COVID-19-a promising target?. Haematologica, 105(12), 2847.

Mastellos, D. C., da Silva, B. G. P., Fonseca, B. A., Fonseca, N. P., Auxiliadora-Martins, M., Mastaglio, S., ... & Lambris, J. D. (2020). Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clinical Immunology, 220, 108598.

Röth, A., Nishimura, J. I., Nagy, Z., Gaàl-Weisinger, J., Panse, J., Yoon, S. S., ... & Peffault de Latour, R. (2020). The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood, 135(12), 912-920.

Martínez-López, D., Roldan-Montero, R., García-Marqués, F., Nuñez, E., Jorge, I., Camafeita, E., ... & Martin-Ventura, J. L. (2020). Complement C5 protein as a marker of subclinical atherosclerosis. Journal of the American College of Cardiology, 75(16), 1926-1941.

Reichhardt, M. P., Johnson, S., Tang, T., Morgan, T., Tebeka, N., Popitsch, N., ... & Lea, S. M. (2020). An inhibitor of complement C5 provides structural insights into activation. Proceedings of the National Academy of Sciences, 117(1), 362-370.

Jendza, K., Kato, M., Salcius, M., Srinivas, H., De Erkenez, A., Nguyen, A., ... & Michaud, G. A. (2019). A small-molecule inhibitor of C5 complement protein. Nature chemical biology, 15(7), 666-668.

Fukuzawa, T., Sampei, Z., Haraya, K., Ruike, Y., Shida-Kawazoe, M., Shimizu, Y., ... & Nezu, J. (2017). Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Scientific reports, 7(1), 1-12.

Keshari, R. S., Silasi, R., Popescu, N. I., Patel, M. M., Chaaban, H., Lupu, C., ... & Lupu, F. (2017). Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model of Escherichia coli sepsis. Proceedings of the National Academy of Sciences, 114(31), E6390-E6399.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Cynomolgus Recombinant C5 protein?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Alternative Versions

Mouse Recombinant C5a protein (CAT#: V2LY-0526-LY10)

Mouse Recombinant C5a protein, Biotin Conjugated, (CAT#: V2LY-0526-LY11)

Human Recombinant C5 protein (CAT#: V2LY-0526-LY3329)

Human Recombinant C5 protein, His Tag (CAT#: V2LY-0526-LY3331)

Cynomolgus Recombinant C5 protein, His Tag (CAT#: V2LY-0526-LY1473)

Human Recombinant C5 protein, His & Flag Tag (CAT#: V2LY-0526-LY9)

Human Recombinant C5 protein, His & Flag Tag-1 (CAT#: V2LY-0526-LY3328)

Human Recombinant C5 protein, Flag Tag (CAT#: V2LY-0526-LY3330)

Related Products

Mouse Recombinant C5a protein (CAT#: V2LY-0526-LY10)

Mouse Anti-C5 Recombinant Antibody (CBFYC-0231) (CAT#: CBMAB-C0258-FY)

Human Recombinant C5 protein, His & Flag Tag-1 (CAT#: V2LY-0526-LY3328)

Human Anti-C5 Recombinant Antibody (CBFYC-0657) (CAT#: CBMAB-C0711-FY)

Human Recombinant C5 protein, Flag Tag (CAT#: V2LY-0526-LY3330)

Rabbit Anti-C5 Recombinant Antibody (215) (CAT#: CBMAB-C4385-LY)

Human Recombinant C5 protein, His Tag (CAT#: V2LY-0526-LY3331)

Mouse Recombinant C5a protein, Biotin Conjugated, (CAT#: V2LY-0526-LY11)

Human Recombinant C5 protein, His & Flag Tag (CAT#: V2LY-0526-LY9)

Mouse Anti-C5 Recombinant Antibody (
13H2) (CAT#: V2LY-0725-LY615)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry